Immunoreactivity of apolipoprotein B-100 in oxidatively modified low density lipoprotein. 1994

N V Valentinova, and Z W Gu, and M Yang, and E V Yanushevskaya, and I V Antonov, and J R Guyton, and C V Smith, and A M Gotto, and C Y Yang
Department of Medicine, Baylor College of Medicine, Houston, Texas 77030.

Thirteen monoclonal antibodies (MAbs) against apolipoprotein B-100 (apo B) were used to analyze changes in immunoreactivity of human LDL resulting from oxidation mediated by cupric ions and oxygen. Decrease in immunoreactivity of oxidized LDL was demonstrated by competitive ELISA with MAbs 5F8, BL3, Mb43, 2G8, B3, B5, and BL7 for which the epitopes are located within residues 1-1297, 4235-4355, 4027-4081, 3728-4306, 2239-2331, 1854-1878, and in the vicinity of residue 2331, respectively. Immunoreactivity of the epitope B6 (2239-2331) increased during first 4 hours of oxidation and then diminished gradually. Epitope B1 (405-539) had slightly reduced immunoreactivity during first 8 h of LDL oxidation and then its minor increase was observed. MAb 12G10, specific to the epitope within apo B thrombin-digest fragment T4 (1-1297), displayed either weak or strong binding to LDL. LDL with weak binding pattern demonstrated significant increase in immunoreactivity upon oxidation. In contrast, LDL with strong binding pattern showed little to no change. Epitopes Mb47 (3441-3569) and 8G4 (1-1297) remained unchanged in oxidized LDL. Immunoreactivity of apo B-100 epitope recognized by MAb 4C11 (residues 2377-2658) was shown to be a function of oxidation time: it increased progressively up to 16 h and was stabilized for another 24 h of LDL oxidation. This epitope may be unmasked by LDL oxidation and may provide a useful immunochemical marker to monitor the extent of LDL oxidation.

UI MeSH Term Description Entries
D008077 Lipoproteins, LDL A class of lipoproteins of small size (18-25 nm) and light (1.019-1.063 g/ml) particles with a core composed mainly of CHOLESTEROL ESTERS and smaller amounts of TRIGLYCERIDES. The surface monolayer consists mostly of PHOSPHOLIPIDS, a single copy of APOLIPOPROTEIN B-100, and free cholesterol molecules. The main LDL function is to transport cholesterol and cholesterol esters to extrahepatic tissues. Low-Density Lipoprotein,Low-Density Lipoproteins,beta-Lipoprotein,beta-Lipoproteins,LDL(1),LDL(2),LDL-1,LDL-2,LDL1,LDL2,Low-Density Lipoprotein 1,Low-Density Lipoprotein 2,LDL Lipoproteins,Lipoprotein, Low-Density,Lipoproteins, Low-Density,Low Density Lipoprotein,Low Density Lipoprotein 1,Low Density Lipoprotein 2,Low Density Lipoproteins,beta Lipoprotein,beta Lipoproteins
D010084 Oxidation-Reduction A chemical reaction in which an electron is transferred from one molecule to another. The electron-donating molecule is the reducing agent or reductant; the electron-accepting molecule is the oxidizing agent or oxidant. Reducing and oxidizing agents function as conjugate reductant-oxidant pairs or redox pairs (Lehninger, Principles of Biochemistry, 1982, p471). Redox,Oxidation Reduction
D003300 Copper A heavy metal trace element with the atomic symbol Cu, atomic number 29, and atomic weight 63.55. Copper-63,Copper 63
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D000939 Epitopes Sites on an antigen that interact with specific antibodies. Antigenic Determinant,Antigenic Determinants,Antigenic Specificity,Epitope,Determinant, Antigenic,Determinants, Antigenic,Specificity, Antigenic
D001055 Apolipoproteins B Major structural proteins of triacylglycerol-rich LIPOPROTEINS. There are two forms, apolipoprotein B-100 and apolipoprotein B-48, both derived from a single gene. ApoB-100 expressed in the liver is found in low-density lipoproteins (LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL). ApoB-48 expressed in the intestine is found in CHYLOMICRONS. They are important in the biosynthesis, transport, and metabolism of triacylglycerol-rich lipoproteins. Plasma Apo-B levels are high in atherosclerotic patients but non-detectable in ABETALIPOPROTEINEMIA. Apo-B,Apo B,ApoB,Apoprotein (B),Apoproteins B
D017392 Thiobarbituric Acid Reactive Substances Low-molecular-weight end products, probably malondialdehyde, that are formed during the decomposition of lipid peroxidation products. These compounds react with thiobarbituric acid to form a fluorescent red adduct. TBARs
D053299 Apolipoprotein B-100 A 513-kDa protein synthesized in the LIVER. It serves as the major structural protein of low-density lipoproteins (LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL). It is the ligand for the LDL receptor (RECEPTORS, LDL) that promotes cellular binding and internalization of LDL particles. Apo B-100,Apo-B-100,ApoB-100,Apo B 100,ApoB 100,Apolipoprotein B 100

Related Publications

N V Valentinova, and Z W Gu, and M Yang, and E V Yanushevskaya, and I V Antonov, and J R Guyton, and C V Smith, and A M Gotto, and C Y Yang
October 1989, Journal of lipid research,
N V Valentinova, and Z W Gu, and M Yang, and E V Yanushevskaya, and I V Antonov, and J R Guyton, and C V Smith, and A M Gotto, and C Y Yang
November 1999, Biochemistry,
N V Valentinova, and Z W Gu, and M Yang, and E V Yanushevskaya, and I V Antonov, and J R Guyton, and C V Smith, and A M Gotto, and C Y Yang
June 2007, Proteomics,
N V Valentinova, and Z W Gu, and M Yang, and E V Yanushevskaya, and I V Antonov, and J R Guyton, and C V Smith, and A M Gotto, and C Y Yang
January 1990, Free radical research communications,
N V Valentinova, and Z W Gu, and M Yang, and E V Yanushevskaya, and I V Antonov, and J R Guyton, and C V Smith, and A M Gotto, and C Y Yang
January 1999, Pediatric research,
N V Valentinova, and Z W Gu, and M Yang, and E V Yanushevskaya, and I V Antonov, and J R Guyton, and C V Smith, and A M Gotto, and C Y Yang
August 1995, Diabetologia,
N V Valentinova, and Z W Gu, and M Yang, and E V Yanushevskaya, and I V Antonov, and J R Guyton, and C V Smith, and A M Gotto, and C Y Yang
August 1993, Atherosclerosis,
N V Valentinova, and Z W Gu, and M Yang, and E V Yanushevskaya, and I V Antonov, and J R Guyton, and C V Smith, and A M Gotto, and C Y Yang
March 2017, The International journal of angiology : official publication of the International College of Angiology, Inc,
N V Valentinova, and Z W Gu, and M Yang, and E V Yanushevskaya, and I V Antonov, and J R Guyton, and C V Smith, and A M Gotto, and C Y Yang
July 1995, Analytical biochemistry,
N V Valentinova, and Z W Gu, and M Yang, and E V Yanushevskaya, and I V Antonov, and J R Guyton, and C V Smith, and A M Gotto, and C Y Yang
January 1983, Artery,
Copied contents to your clipboard!